F. Dane Et Al. , "Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study," BMJ OPEN , vol.10, no.3, 2020
Dane, F. Et Al. 2020. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. BMJ OPEN , vol.10, no.3 .
Dane, F., Ozgurdal, K., YALÇIN, Ş., Benekli, M., Aykan, N. F., YÜCEL, İ., ... ÖZKAN, M.(2020). Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. BMJ OPEN , vol.10, no.3.
Dane, Faysal Et Al. "Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study," BMJ OPEN , vol.10, no.3, 2020
Dane, Faysal Et Al. "Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study." BMJ OPEN , vol.10, no.3, 2020
Dane, F. Et Al. (2020) . "Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study." BMJ OPEN , vol.10, no.3.
@article{article, author={Faysal Dane Et Al. }, title={Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study}, journal={BMJ OPEN}, year=2020}